TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
Description
Results
NMA
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
abdominal aortic aneurysm
acute coronary syndrome
acute heart failure
acute myocardial infarction
advanced breast cancer (metastatic)
atrial fibrillation
atrioventricular block or sick sinus syndrome
CABG surgery
cardiac arrest
cardiovascular prevention
carotid stenosis
coronary artery disease
diabetes type 2
diabetic kidney disease
Head and neck cancer
heart failure
hypertension
miscellaneous
multiple myeloma
obesity and overweight
patients at high risk for cardiovascular events
percutaneous coronary intervention
peripheral vascular diseases
post acute coronary syndromes
post myocardial infarction
prevention of sudden death
pulmonary embolism
restenosis after PCI
stable angina
stent
superficial thrombophlebitis
thrombosis prevention
throracic aortic aneuvrism
venous thrombosis
a
acarbose
acetamin
acute short term calcium blockers
angiotensin receptor blocker
angiotensin-converting enzyme inhibitors
anti-agrégant
antiarryhtmic
antibiotics
anticoagulant
anticoagulants + antiplatelet agents
antioxydant
antiplatelet drugs
antivitamins K
ARBs added to ACEI
beta radiation
beta-blockers + diuretics
beta-blockers or diuretics
BNP-guided management
CABG
calcium-channel blockers
cardiac resynchronization therapy
Catheter aspiration devices
CETP inhibitor
Combined CRT + ICD
compression-only CPR
cooling-off strategy
diet
diuretics
docetaxel based induction CT
double stenting
drug-eluting stents
early angioplasty (<3 days) after thrombolysis
early invasive strategy
embolic protection devices
endothelin receptor antagonist
endovascular repair
Enzyme therapy
Essaven
Etofenak
exercise training
Exhirud
extended prophylaxis
fibrinolysis
fibrinolytic
Fixed-dose LMWH
Fluoxetine
gamma radiation
GCS (adjunctive therapy)
GIK infusion
GP IIaIIIb inhibitors
Graduated compression stockings
Heparansulphate
heparin
home treatment
hydralazine-ISDN
Implantable cardioverter defibrillator therapy
induced HbA1c reduction
induction polyCT with platin
induction polyCT without platin
intensive treatment
Interleukin-1ß inhibition
intravenous nitrates
IPC adjunctive therapy
IPC monotherapy
Larynx preservation
LLA closure
Long term treatment
Low molecular weight heparin
Mechanical thrombectomy devices
Multiple risk factor interventions
non-polymeric ES
NSAIDs
omega-3 Fatty acids
oral anticoagulant
oral platelet GP IIbIIIa receptor inhibitor
other cholesterol lowering drugs
other induction CT
Others class I
pacemaker
PCI
PF induction CT
Phosphodiesterase III inhibitors
plasma homocysteine lowering intervention
platelet aggregation inhibitors
prazosin
Prehospital thrombolysis
pretreatment with statin
primary PCI
prolonged dual antiplatelet therapy
prophylactic lidocaine
Prophylactic LMWH
repeat fibrinolysis
rescue PCI
resordable
Rhythm control
rimonabant
screening for CAD
short term LMWH
spinal cord stimulation
statins
stem cells
surgery
sympathectomie avec chirurgie
synthetic oligosaccharide
systemic fibrinolysis
telemonitoring
tesofensine
Therapeutic LMWH
thrombectomy
Topical methylthioadenosine
transfer for primary angioplasty
transmyocardial revascularization
triple antiplatelet
Vasotonin
vs angioplasty
vs antithrombotics
vs control
vs control or placebo
vs conventional PCI
vs LMWH
vs no anticoagulant
vs no screening
vs no systematic PCI
vs on pump CABG
vs pentascharide
vs placebo
vs placebo or control
vs placebo or no treatment
vs standard strategy
vs surveillance
vs usual care
vs active treatment
vs angiotensin-converting enzyme inhibitors
vs anticoagulant
vs antiplatelet drugs
vs calcium blockers
vs calcium-channel blockers
vs dextran
vs diuretic and/or beta-blocker
vs diuretic or beta-blocker
vs diuretics
vs drug-eluting stents
vs fondaparinux
vs GCS
vs ICD
vs IPC
vs Low molecular weight heparin
vs no TMR
vs non active control
vs open surgery
vs other fibrinolytic
vs rate control
vs short antiplatelet drug
vs single stenting
vs standard CPR
vs surgery
vs thrombolytic
vs UFH
vs Unfractionated heparin
aaa
abdominal surgery
acute coronary syndrome
diabetic patients
general surgery
heart failure
hip surgery
knee surgery
medical patients
primary prevention
All cause death
Coronary death
Coronary event
Adverse events
Amputations
Bleeding
Cardiovascular death
Death from cancer
MACE
Fatal MI
Heart failure
In-hospital death
urgent CABG
Amputation
Revascularization
Surgical revascularization
Infection
Long term death
Treatment related complication
Major bleeding
Minor bleeding
Haemmorhagic stroke
Vascular death
Fatal stroke
Non fatal stroke
Non fatal MI
Vascular events
Fatal bleeding
Non cerebral major bleeding
Stroke or MI
Cancer
Rhabdomyolysis
thrombo-embolic event (cerebral or systemic)
ischemic stroke
hypertransaminasemia
intracranial hemorrhage
TE event or ischemic stroke or systemic embolism
short term death
Extracranial hemorrhage
augmentation de la distance de claudication initiale
augmentation de la distance de claudication
GI adverse events
Occlusion
Global improvement
Serious adverse event
Relief of constipation
relief of abdominal pain
évenement stoxiques cardiaques
Sepsis
Bacteriuria
Urinary infection
Febrile morbidity
Wound infection
Postoperative intra abdominal abcess
Non vascular death
Deaths or MI
rehospitalization
CCS class III-IV angina
In hospital death or MI
In hospital non fatal MI
stroke (fatal and non fatal)
Precoce death or MI
myocardial infarction (fatal and non fatal)
Death from any cause or hospitalization for any reason
hospitalisation for heart failure
Cough
Recurrent thromboembolic event
Thrombus extension
Short term haemorrhage
Symptomatic pulmonary embolism
Deep vein thrombosis
death associated with abdominal aortic aneurysms
Bacteremia
Abdominal infection
Intraperitoneal abces
peritonitis
pneumonia
fistula
perineal infection
infection related death
Sudden death
cardiac death
reinfarction
cardiovascular events
cardiac event (fatal and non fatal )
serious hyperkalemia
death from cardiovascular causes or hospitalization for cardiovascular causes
hospitalisation for cardiovascular causes
weight loss equal to or greater than 10 percent
weight loss equal to or greater than 5 percent
weight change from baseline (kg)
Waist circumference change from baseline (cm)
Fasting glucose change (mmol/liter)
DBP change from baseline (mmHg)
SBP change from baseline (mmHG)
weight change from baseline (%)
ADAS-COG at 6 months
MMSE at 6 months
SIB score at 6 months
ADCS-ADL-severe at 6 months
withdrawals due to an adverse event at 24 weeks
CIBIC+ score at 6 months
NPI at 6 months
DAD at 6 months
agitation
CIBIC-Plus or CGIC (numbers improved) at 24 weeks
CDR-SB at 24 weeks
GBS at 52 weeks
ADAS-COG at 12 weeks
MMSE at 12 weeks
MMSE at 52 weeks
long term institutionalisation at 52 weeks
CDR-SB at 12 weeks
larynx preservation
death or disease progression (progression free survival)
NPI at 3 months
withdrawals at 3 months
A CHANGER
vomiting
diarrhoea
adverse event at 1 year
no change or worsening in CIBIC+ at 6 month
less than 4 points improvement in ADAS-cog at 6 months
complete response to induction CT
treatment related death
death or laryngectomy
All grade 3 to 4 events during induction CT
neutropenia (grade 3-4) during induction CT
complete response to study treatment
Toxic death during induction CT
All grade3-4 events during study treatment
treatment failure
death (overall survival)
death or event (event free survival)
remission
Leukemia free survival
Pancreatitis
Severe allergic reactions
Allergic reactions
CNS thrombosis
Hyperglycemia
Diabetes
second malignancy
severe infection
relapse
Relapse Marrow only
Relapse involving CNS
complete remission
thrombotic events
remission failure after induction
response at 2h
pain free at 2h
response at 4h
pain free at 4h
any adverse event
response at 1h
headache recurrence
use of rescue medication
fatigue
chest symptoms
Neck tightness
dizziness
somnolence
nausea
use of a second dose
rest HR
disease free survival
progression or death (progression free survival PFS)
laryngectomy
death of unknown cause
cancer related death
Survival with functional larynx
pain free at 1h
sustained response at 24hr
sustained pain-free at 24h
response at 4h without additionnal treatment
Stent thrombosis (any, end of follow up)
target lesion revascularisation
angiographic restenosis
4 yr mortality from all causes
4 yr TLR
4 yr MI
4 yr death or MI
4 yr stent thrombosis
4y stent thrombosis (ARC)
recurrent angina
Drop in platelet count of 50%
death, myocardial infarction, or recurrent at 14 days
CABG
PTCA
no angina (at 6 weeks)
Positive 6-wk ETT
Hypotension
Emergency CABG
Reocclusion
Adverse events leading to treatment discontinuation
angiodema
Coronary death and non fatal MI
Myopathy
LDL
Diabetes onset
Angina
Peripheral arterial disease
End stage renal disease
non cardiovascular death
Cardiac death or MI
Death, MI and stroke
In-hospital death
In-hospital MI
long term MI
proximal DVT
distal DVT
non-fatal pulmonary embolism
asymptomatic DVT
total VTE and all-cause mortality
asymptomatic proximal DVT
Venous thromboembolism
wound haematoma / infection
fatal pulmonary embolism
death or severe congestive heart failure
NYHA class improvement
maximal walking distance
pain-free walking distance
All-cause hospitalisation
exacerbation of heart failure
macrovascular events
microvascular events
nephropathy
retinopathy
macrovascular or microvascular events
fatal HF
Peripheral vascular events
atrial fibrillation
urgent target vessel revascularisation
Final TIMI 3 flow
Initial TIMI 3 flow
Symptomatic venous thromboembolism (DVT, PE)
transfusion
Complete clot lysis (early)
Mortality (early)
Pulmonary embolism (early)
Bleeding (early)
Any improvement in venous patency (early)
Normal venous function (late)
Complete clot lysis (late)
Post-thrombotic syndrome (late)
Mortality (late)
Leg ulceration (late)
Stroke/intracerebral bleeding (early)
stroke or TIA
Peripheral embolism
Atrial fibrillation follow-up
Hospitalization for any reason
Pro-arrhythmia
Worsening heart failure
Transplantation
Arrhythmia
Vertigo
Ventricular fibrillation
II-III atrio ventricular block
Cardiogenic shock
severe arrhythmia
Bradycardia
Flushing
confirmed myocardial infarction
early death
Pacemaker syndrome
stroke or death
Perioperative stroke or death or any subsequent stroke
Perioperative stroke or death or subsequent ipsilateral stroke
Perioperative stroke or death
myocardial infarction or death
death, myocardial infarction, or recurrent at 30 days
death at 30 days
myocardial infarction at 30 days
all cause death, MI, thrombo-embolic stroke
death, MI, unplanned revascularization
ischemic events + bleeding
major bleeding TIMI
1 year MI
1 year death from any cause
TIMI minor bleeding
cardiovascular death, MI, stroke
pulmonary embolism (symptomatic and asymptomatic)
late stent thrombosis (31days - 1year)
target-vessel revascularization
2 yr TLR
2 yr MACE
in-lesion binary restenosis
2 yr Death (all cause)
Acute stent thrombosis (<=24h)
sub acute stent thrombosis (1-30 days)
late death
refractory ischemia
fatal bleeding
non fatal VF
fatal and non fatal ventricular fibrillation
fatal ventricular fibrillation
Severité globale
Fatigue
Sommeil
Dépression
Anxiété
FIQ
Douleur
Points douloureux (nombre)
Sheehan disability scale
CGI-severity
Patient Global Impression of Improvement (PGI-I)
HAQ functional disability
Death from any cause or hospitalization for heart failure
Hyperkalaemia
long term revascularization
Recurrent Symptomatic Venous Thromboembolism or death
5-year death
7-year death
10-year death
death, reinfarctus, stroke
Death, MI, ischameia
amélioration globale (patient)
amélioration globale (clinicien)
depression - échelle de Beck
Growth rate in mm/year
Myocardial ischemia
CV death, MI hospitalization for HF
Angina episodes per week
Nitroglycerin use per week
Extension and/or recurrence of SVT
Pain disappearance
Heparin-induced thrombocytopenia
Venous thromboembolism end of treatment
recurrent symptomatic venous thromboembolism and death at the end of treatment
symptomatic venous thromboembolism at the end of treatment
Angina class improvement + death
Angina relief
Cardiac arrhythmic death
Vascular noncardiac death
Cardiac nonarrhythmic death
hospitalization for AF
Atrial fibrillation recurrence
Survival to hospital discharge
Return of spontaneous circulation
death or hospitalization
unstable angina
Death or any stroke within 30 days
Death during follow up
Death or any stroke (during follow up)
Death or stroke or myocardial infarction
Stroke within 30 days
Death within 30 days
Death or disabling stroke within 30 days
Stroke during follow up
Death or neurological complication within 30 days
taille en fin d'essai SDS
changement taille (cm)
changement taille SDS
vitesse de croissance SDS
vitesse de croissance (1 an)
succès thérapeutique
changement vitesse de croissance SDS
changement vitesse de croissance (cm/an)
taille en fin d'essai (cm)
taille définitive (cm)
taille définitive SDS
major VTE (fatal and non fatal DVT,PE)
death or hospitalization for cardiac causes
puylmonary embolism
non cardiac death
Carotid revascularization
Coronary revascularization
new-onset diabetes
new-onset atrial fibrillation
new cardiac revascularization
Repeat intervention
Death, MI, stroke, refractory ischemia
death or cardiovascular hospitalization
Cardiovascular death or hospital admission for CHF
device retrieval, pericardial effusion, major bleeding
stroke, cardiovascular or unexplained death, systemic embolization
death or vein graft failure
change in mean CIMT
change in maximum CIMT
Major or minor TIMI bleeding
Urgent target-vessel revascularization
all cause death, MI, stroke
death or nonfatal CHF events
heart failure death
Gastrointestinal major bleeding
Non-lifethreatening major bleeding
Lifethreatening major bleeding
MI (CK-MB >3x ULN at 6 and 12 hours after PCI)
MI (troponin I >3x ULN at 6 and 12 hours after PCI)
30-day death
In hospital aneurysm-related death
long term aneurysm-related death
NYHA change
LV ejection fraction
exercise capacity
Acute coronary syndrome
PCI
Hospitalization for angina
Symptomatic deep-vein thrombosis
Late lumen loss
Change in MLD
BNP under treatment
1 year event
6 months MI
6 months events
1 year revascularization
6 months death
long term cardiovascular events
long term fatal stroke
non-perioperative ipsilateral stroke
long term stroke
long term restenosis
Cranial neuropathy within 30 days
cardiovascular events at 4 months
cardiovascular events at 1 month
total cholesterol (at 1 y)
HDL (at 1 y)
major or clinically relevant non-major bleeding
death by cardiac arrhythmia
combined endpoint
graft occlusion
carotide IMT
Death related to diabetes
Time to 1 mm ST depression (s)
Time to angina onset (s)
Total exercise duration (s)
vision loss
severe hypoglycemia
long term cardiovascular death
long term all cause death, MI
1-year death or MI
renal death
favorable neurologic outcome at discharge
Smoking prevalence
blood cholesterol concentration
net benefit
non pulmonary embolism death
Pain at rest (VAS)
WOMAC index
paracetamol consumption
Pain during activity (VAS)
NSAID consumption
Algo-functional Index (AFI)
amelioration of Dyspnea at 24 h
Amelioration of Dyspnea at 6 h
death from cardiovascular causes or hospitalization for heart failure
Pain during activity at 6 months
Pain during activity at 3 months
OMERACT-OARSI responders
HbA1c
lung cancer
breast cancer
prostate cancer
any bleedings
clinical vertebral fractures
vertebral fractures
non vertebral fractures
hip fractures
major non vertebral fractures
morphometric vertebral fractures
1-year vertebral fracture
1-year non vertebral fracture
long-term survival
GUSTO severe/moderate bleeding
Cardiovascular death/MI/stent thrombosis
stent thrombosis
Venous thromboembolism or death
proximal deep-vein thrombosis
RP product at rest
AFI
EVA
major non vertebral fractures (imputed)
systemic thrombo-embolic complication
serious adverse events
IOP at 3 months (mmHg)
IOP change at 3 mo, absolute (mmHg)
IOP at end (mmHg)
hyperhemia or ocular redness
Digit Symbol test
Trail B test
Trail A test
Grooved Pegboard
Rey auditory verbal learnin
VTE
progression (Time to progression TTP)
death from all causes as adverse event
cardiovascular events as adverse event
Muscle-related adverse events
Neurocognitive disorder
neurological SAE
myocardial infarction as adverse event
cardiovascular death as adverse event
unstable angina as adverse death
cardiovascular events including revascularization
pdf
pathology
Demonstrated benefit and harm
k
×
Modal title
